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SUMMARY 
Recurrent herpes simplex labialis is associated with mild morbidity, 
but remains a significant problem for people with frequent and/or 
severe recurrences. Both topical and peroral episodic antiviral 
treatments of recurrences are modestly effective at reducing the 
duration of signs and symptoms. Recent studies with high-dose, 
short-course valaciclovir suggest that maximum benefit from 
antiviral therapy may be achieved with as little as 1 day of 
treatment. Topical steroids may be useful in combination with an 
antiviral agent, but more needs to be learnt about the appropriate 
strength and duration of steroid therapy before a general 
recommendation can be made. Selected subgroups of patients are 
candidates for prophylactic treatment with perorally administered 




HERPES SIMPLEX LABIALIS (herpes labialis) is a common 
and ubiquitous infection of the skin resulting from herpes 
simplex virus (HSV). The vast majority of cases are due to 
herpes simplex virus type 1 (HSV-1), although recurrent 
infections due to herpes simplex virus type 2 (HSV-2) have 
been reported. Approximately 20-40% of the population 
will experience labial or perioral outbreaks of vesicular 
herpetic lesions. 1- 4 The frequency of these outbreaks is 
extremely variable, ranging from rare episodes every 
5-10 years in some individuals, to monthly or even more 
frequent outbreaks among a small proportion of patients. 
The severity of the illness is most often mild, although it is 
uncomfortable and disfiguring (Figure 1). In a classic case of 
herpes labialis, six stages ofthe sore are recognized: 
prodrome (localized tingling, itching or burning at the site 
of infection)' erythema, papule/oedema, ulcer, crust (soft 
debris, then hard eschar) and healed (loss of crust). Some 
healed lesions may show one or more minor residual 
abnormalities for several days including swelling, flaking of 
the skin and erythema before the skin is entirely normal in 
appearance. The psychological impact of a proininent facial 
infection, particularly in young patients with frequent or 
severe recurrences, should not be underestimated. In those 
with an underlying immunosuppressing disease, lesions 
have a longer duration and may spread to cause major 
morbidity. Erythema multiforme reactions may complicate 
episodes of herpes labialis and can be temporarily disabling 
(Figure 2).5 Lastly, herpetic keratitis and herpes encephalitis 
are infrequent but grave complications of orofacial HSV-1 
infection.6 
Figure 1: 
Recurrent herpes labialis in the vesicle stage. 
In recent years, major progress has been made in our 
understanding ofHSV infections, and in the development of 
safe and effective antiviral drugs. Nucleoside analogues that 
inhibit HSV replication are available commercially for the 
treatment of herpetic keratitis, herpes genitalis, herpes 
labialis, mucocutaneous HSV infections in immuno-
suppressed hosts, neonatal herpes and herpes encephalitis. 
In the following report, the status of topical and peroral 
treatments for herpes labialis given either 'episodically' (at 
the onset of a recurrence) or chronically in the absence of 
lesions to prevent recurrences (prophylaxis) are reviewed. 
Episodic or prophylactic treatment with antiviral drug 
therapy is the current standard care for recurrent herpes 
Figure 2: 
Erythema multiforme on the hand developing several 
days after an episode of herpes labialis. 
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Table 1: Some over-the-counter medicines 
available for topical treatment of herpes labialis 
in the USA 
• Anbesol® gel (Wyeth, Madison, Nl) 
• Blistex® lip ointment (Blistex, Inc., Oak Brook, IL) 
• Campho·Phenique® (Bayer Corporation, Pittsburgh, PAl 
• Herpecin-L ® (Chattem, Inc., Chattanooga, TN) 
• Viractin® OB Williams Co., New Jersey, NJ) 
• Zilactin® (Zila Pharmaceuticals, Inc., Phoenix, AZ) 
• Abreva® (Avanir Pharmaceuticals, San Diego, CAl 
labialis infections. A variety oftopical over-the-counter 
(OTC) preparations are also available (Table 1), butin the 
majority of cases the mechanism of action is not clear, and 
rigorous clinical trials to define efficacy have not been 
performed. Abreva® (n-docosanoll0% cream) is the most 
intensively studied OTC product to date, and has recently 
been approved for OTC sale in the USA. Two large trials 
were performed, one in which Abreva®had no benefit, and 
another in which there was a small positive effect (Table 2). 
The mechanism of action of n-docosanol is unclear.7,8 
Topical Antiviral Therapy 
Demonstration of the clinical efficacy of topical 
formulations of antiviral drugs among 
immunocompetent patients has been difficult. Lesion 
severity varies markedly and necessitates large numbers 
of patients, natural healing oflesions is rapid, and it is 
difficult to find a topical drug formulation that 
facilitates skin penetration without causing undue skin 
irritation. 9- 11 The results of recent trials are summarized 
in Table 2. 
ACICLOVIR 
Studies of aciclovir ointment in immunocompetent 
individuals have provided little to no evidence of 
efficacy.12-15 Aciclovir ointment was effective for herpes 
labialis in immunocompromised patients, however, and 
has been approved for this indication in the USA.16 
Aciclovir was shown to penetrate human skin more 
effectively in cream rather than ointment formulation. 17 
Accordingly, data supporting the efficacy of aciclovir cream 
have been obtained more readily than with the ointment, 
and sufficient have been gathered to support licensure in 
European countries, albeit the studies in the literature were 
small (n=30-51),18-20 and one negative report has been 
published. 21 Using a more robust and modern protocol, we 
have recently re-examined the efficacy of aciclovir cream in 
two large, independent clinical trials. 22 The mean duration 
of recurrent episodes was statistically significantly shorter 
(P<O.Ol) with aciclovir cream (4.4 days and 4.6 days in the 
respective trials) than with placebo cream (4.8 days and 
5.2 days, respectively). There was no effect on the 
frequency of aborted lesions (Table 2). 
Table 2: Randomized, double-blind, placebo-controlled, parallel-group, patient-initiated studies 
evaluating earlya episodic topical antiviral therapy of naturally recurrent herpes labialis in 
immunocompetent patients 
Study 
Spruance et al., 
199041 
Spruance et al., 
199711 




Sacks et al., 
2001 43 
Spruance et al., 
200122 
Treatment arms 
Idoxuridine 15% in 
dimethyl sulphoxide 
or dimethyl sulphoxide 
or water every 3 hours 
for 4 days 
Penciclovir 1 % cream or 
drug vehicle every 
2 hours for 4 days 
Penciclovir 1 % cream 
or water every 2 hours 
for 4 days 
n-docosanol 10% cream 
or stearic acid-containing 
creamd 
n-docosanol 10% cream 
or polyethylene glycol 
ointment control every 
3 hours until healing 
Aciclovir 5% cream 
or drug vehicle every 










"Initiation of treatment in the prodromal or erythema lesion stage. 
Reduction in healing 
time compared with 
placebo (%)b 























bHealing time was usually measured from the start of treatment to the cessation of all signs and symptoms for 'all 
patients', and from the start of treatment to the loss of crust for 'classical lesions'. Numbers given were statistically 
significant but may have been secondary end-points. Where more than one study was performed, the combined results 
are presented. 
cClassical lesions are those that progress to the vesicle, ulcer and/or crust stage. 
dThe dosing frequency was not reported in this study. 
NS, not significant; ND, not done. 
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PENCICLOVIR 
Penciclovir cream improved lesion healing in two 
randomized, double-blind trials, and was approved for 
the treatment of herpes labialis in the USA and other 
countries. 11 ,23 Healing time was reduced by 13-17% 
compared with vehicle cream control (P<O.OOl). A 
further study of penciclovir cream was performed to see 
if the vehicle cream control used in these trials had a 
beneficial effect on herpes labialis healing, confounding 
the exact benefits attributable to penciclovir.24 In this 
follow-up trial, penciclovir cream was compared with a 
purified water control for the treatment of sun-induced 
recurrences. The cream reduced median time-to-Iesion 
healing by 1.1 days or 19% (P=O.OOl; Table 2). In the 
sun-induced study, there was a greater magnitude of 
benefit (1.1 days) than in the registration trials (0.7 days). 
Sun-induced lesions are more severe than herpes labialis 
from other causes, however, such that the reduction in 
lesion duration was approximately the same in the two 
studies (13-17%11 versus 19%24). These data provide 
evidence that the penciclovir cream vehicle does not 
have confounding antiviral or wound-healing properties, 
substantiating the outcome of the registration trials. 
Peroral Antiviral Therapy 
Peroral therapy of herpes labialis was investigated when it 
became apparent that topical therapy might be limited by 
poor penetration of nucleoside antivirals through the stratum 
corneum. To date, the two agents that have been studied are 
aciclovir and valaciclovir (Table 3). 
Raborn et al. 25 treated patients through three consecutive 
episodes of herpes labialis with peroral aciclovir (200 mg five 
times daily for 5 days). The healing time of classical lesions 
was reduced by 12-17% compared with placebo control. 
This difference was statistically significant for the first two 
episodes, and there was a trend in the third. Aciclovir had a 
dramatic effect (30--40% reduction in healing time) on the 
severity of secondary lesions (those appearing after the onset 
of the firstlesion and thus developing during therapy), 
demonstrating the critical relationship of efficacy to the 
timing of therapy. Spruance et al. 26 used higher doses of 
aciclovir (400 mg five times daily for 5 days), and reduced 
healing time by 27% compared with placebo (P=0.03) in 
patients who started treatment in the prodrome or erythema 
lesion stage. In neither of these two peroral aciclovir studies 
did treatment abort lesion development. 
In two studies, Spruance et aI.27 examined the feasibility 
of a high-dose, short-course oral regimen of valaciclovir for 
the acute treatment of herpes labialis. Participants were 
randomized to one of three treatment arms (valaciclovir 
2000 mg twice daily for 1 day; valaciclovir 2000 mg twice 
daily for 1 day, then 1000 mg twice daily for 1 day; or 
placebo), and were instructed to begin treatment within 
1 hour of the first prodromal symptom and before the 
development of any signs of the disease. For the two studies, 
the mean healing times of classical lesions for 1 day of 
valaciclovir treatment were 4.8 and 5.1 days, respectively; for 
2 days of treatment, 5.0 and 5.2 days, respectively; and for 
2 days of placebo treatment, 6.1 and 6.4 days, respectively 
(all comparisons with placebo were statistically significantly 
different, but 1 and 2 days of active treatment were not 
different). When the data from the two studies were 
combined, there was a statistically significant increase in the 
frequency of aborted lesions among the valaciclovir-treated 
patients. 
Treatment of Experimental Ultraviolet 
Radiation-induced Herpes Labialis 
We developed a technique for the systematic induction of 
herpes labialis with experimental ultraviolet radiation 
(UVR) in susceptible volunteers.28 Using this technique, 
approximately 50% of exposed individuals develop 
lesions. The purpose of the model was to provide a rapid 
and sensitive means of testing new treatments for herpes 
labialis, and to study the relationship between drug 
efficacy and the timing oftherapy. Since 1985, we have 
studied a variety oftopical and systemic antiviral and 
anti-inflammatory agents in this model (Table 4). The 
efficacy of therapy in the UVR-induced model has 
generally been more favourable than in field trials 
because ofthe greater severity ofUVR-induced lesions, 
the ability to select therapy-sensitive lesions and ensure 
early initiation of treatment. As shown in Table 4, 
Table 3: Randomized, double-blind, placebo-controlled, parallel-group, patient-initiated studies evaluating 
earlya episodic peroral antiviral therapy of naturally recurrent herpes labial is in immunocompetent patients 
Reduction in healing 
Total study time compared with 
population placebo (%)1> Other 
Study Treatment arms (n) All patients Classical" lesions findings 
Raborn et al., Aciclovir 200 mg or 149 NS 12-17 None 
198725 placebo capsule five times 
dai Iy for 5 days 
Spruance et al., Aciclovir 400 mg or 174 NS 27 Reduced 
199026 placebo capsule five times symptoms 
dai Iy for 5 days 
Spruance et al., Valaciclovir 2000 mg 1856 1 -day treatment 1-day treatment Reduced 
2002 27 twice daily for 1 day, or 16-18 20-21 symptoms 
valaciclovir 2000 mg 2-day treatment 2-day treatment More aborted 
twice daily for 1 day 13 18-19 lesions 
and 1000 mg twice daily 
for a second day, or 
placebo capsules 
alnitiation of treatment in the prodromal or erythema lesion stage. 
bHealing time was usually measured from the start of treatment to the cessation of all signs and symptoms for 'all 
patients', and from the start of treatment to the loss of crust for 'classical lesions'. Numbers given were statistically 
significant but may have been secondary end-points. Where more than one study was performed, the combined results 
are presented, 
cClassical lesions are those that progress to the vesicle, ulcer and/or crust stage. 
NS, not significant 
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Table 4: Randomized, double-blind, placebo-controlled, parallel-group, patient-initiated studies evaluating 
antiviral therapy of experimental ultraviolet radiation-induced herpes labial is in immunocompetent patients 
Timing of Reduction in healing 
Total study treatment in time compared with 
population relation to onset control (%)a Other 
Study Treatment arms (n) of lesion All patients Classkalb lesions findings 
Spruance et a/., Aciclovir 200 mg or 15 2 days after 35 48 Reduced 
1991 28 placebo capsules irradiation lesion area 
five times daily (66%) 
for 5 days 
Bernstein et a/., Foscarnet 3% cream 125 Immediately after NS 18 Reduced 
199732 or vehicle creamC irradiation lesion area 
(43%) 
Spruance et al., Famciclovir 125 mgt 102 2 days after NO 125 mg The highest 
199929 250 mg, 500 mg or irradiation NS dose 
placebo capsules 250 mg reduced 
three times daily for NS lesion area 
5 days 500 mg (60%) 
48 
Spruance and Famciclovir 500 mg 29 At first sign or NO NS Reduced 
McKeough, plus topical symptom of a symptoms 
200030 corticosteroid three lesion Reduced 
times daily for 5 days lesion area 
or famciclovir 500 mg (70%) 
plus topical vehicle 
control three timeS daily 
for 5 days 
Evans et al., Aciclovir 5%/ 120 2 days after NO 10 More 
200244 hydrocortisone 1 '% irradiation aborted 
cream or lesions 
vehicle creamC (29%) 
"Healing time was usually measured from the start of treatment to the cessation of all signs and symptoms for 'all 
patients', and from the start of treatment to the 1055 of crust for 'classical lesions'. Numbers given were statistically 
significant but may have been secondary end-pOints. Where more than one study was performed, the combined results 
are presented. 
bClassical lesions are those that progress to the vesicle, ulcer and/or crust stage. 
cThe dosing frequency was not reported in this study. 
NS, not significant; NO, not done. 
a number oftreatments have led to a reduced lesion area, 
while this has never been observed in field trials (trials 
among the general population). The sensitivity ofthe 
UVR model allows potential compounds and therapeutic 
strategies to be screened for further development. 
Our studies showed that UVR-induced lesions 
developed in a bimodal fashion: an 'immediate' group 
(0-2 days post-irradiation) and a 'delayed' group 
(3-7 days post-irradiation).28 The immediate lesions had 
the characteristic histological features of herpes labialis, 
but appeared to be resistant to antiviral chemotherapy. 
Topical therapy suppressed neither the immediate nor the 
delayed group, regardless of when it was initiated. 
Systemic therapy begun immediately after irradiation or 
7 days before irradiation suppressed the delayed, but not 
immediate, lesions. Initiating systemic therapy 48 hours 
post-irradiation did not suppress the subsequent delayed 
lesions. Because ofthe latter observation, we have used 
systemic therapy initiated at 48 hours post-irradiation as 
an idealized model of early episodic therapy. 
A dose-ranging study of peroral famciclovir in the 
UVR model was used to investigate whether the apparent 
limited efficacy of antivirals in the treatment of herpes 
labialis was an inherent feature ofthe illness or was due 
to difficulties delivering high doses of drug to the infected 
basal cell layer of the epidermis. 29 In this randomized, 
double-blind, placebo-controlled trial, 248 patients were 
exposed to UVR and treated 48 hours later with 
famciclovir 125 mg, 250 mg or 500 mg, or placebo three 
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times daily for 5 days. Ofthese patients, 102 developed 
delayed UVR-induced lesions and could be used to 
evaluate drug efficacy. Oral famciclovir (500 mg three 
times daily) produced statistically significant, dose-
dependent reductions in time to healing and lesion size, 
reducing the lesion healing time by 48%, from 5.8 days to 
3.0 days (P=0.008), and the maximum lesion area by 60%, 
from 139 mm2 to 55 mm2 (P=0.009). 
To determine the potential utility of anti-inflammatory 
therapy in the treatment of herpes labialis, we compared 
the efficacy of oral famciclovir (500 mg three times daily 
for 5 days) plus a topical corticosteroid gel (0.05% 
fluocinonide, Lidex GeFM, Danbury Pharmacal, Inc., 
Danbury, CT, USA) with famciclovir alone as episodic 
treatment in a randomized, double-blind study of 29 
patients with UVR-induced recurrent herpes labialis.3o 
Therapy was applied within 1 hour of the appearance of 
the first signs or symptoms of a recurrence. The 
combination treatment reduced the maximum lesion size 
by 70%, from 162 mm2 to 48 mm2 (P=0.02), and the 
proportion of patients with lesion pain from 100% to 59% 
(P=0.02) compared with famciclovir monotherapy. There 
was also a trend towards more aborted lesions with 
combination treatment than with famciclovir alone (41 % 
versus 8 %, respectively; P=0.09). The increased benefit 
seen in the topical corticosteroid arm suggests that 
combination antiviral/anti-inflammatory therapy is a 
promising new area for clinical research in herpes labialis. 
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Prophylactic Antiviral Chemotherapy 
Prophylactic peroral chemotherapy for herpes labialis can 
be an effective and appropriate management strategy for 
selected patients. Those who should be considered for this 
approach include: patients with frequent recurrent episodes 
(:2 6 episodes/year); patients with a history of herpes-
associated erythema multiforme; patients anticipating a 
period of intense sun exposure or stress; patients 
undergoing surgical procedures on the trigeminal ganglion 
for relief of tic douloureux: persons undergoing peri-or 
intraoral surgeries such as laser, chemical or abrasive 
cosmetic facial resurfacing; immunocompromised patients; 
patients with herpes gladiatorum; selected healthcare 
professionals to lower the potential for virus transmission; 
and selected persons in the advertising, television and 
entertainment industries to improve facial appearance. 
Both field trials and our experience with aciclovir cream 
and foscarnet cream in the UVR-induced herpes labialis 
model demonstrate that topical therapies are not effective 
for prophylaxis.28,31,32 The most likely reason for this is that 
topical therapy is unable to access the reactivating virus in 
the trigeminal ganglion. Raborn et 01. 33 reported that 
prophylactic aciclovir cream reduced the frequency of 
herpes labialis in skiers, but this study was flawed by the 
potential sun-blocking activity ofthe drug. Aciclovir 
absorbs in the ultraviolet B range, such that the stimulus to 
reactivation would be reduced in the aciclovir cream 
recipients. 
Despite its frequency, the industry has paid little 
attention to prophylaxis of herpes labialis compared with 
the research invested in the prevention of genital herpes. 
Reported experience with peroral antiviral nucleoside 
prophylaxis of herpes labialis is summarized in Table 5. 
Raborn et 01.34 were unable to prevent sun-induced herpes 
labialis with peroral aciclovir. Since prophylaxis may be 
ineffective against 'immediate' lesions occurring within the 
first 2 days of UVR exposure,28,35 their study may have been 
confounded by including the many individuals who were 
followed for only a few days. In contrast, in our study of 
147 skiers, who had all experienced UVR-exposure 
triggered facial HSV recurrences in the past, aciclovir 
(400 mg twice daily) or placebo was taken 12 h before the 
first anticipated exposure, and continued for a maximum of 
7 days.35 Significantly fewer individuals receiving aciclovir 
developed lesions than placebo recipients (7% versus 26%, 
respectively; P=O.OOl). For unknown reasons, the overall 
results are less impressive than those seen with similar 
doses in the prophylaxis of genital herpes. It would be 
valuable to perform a dose-ranging study to see if higher 
doses might be more effective. 36 
Rooney et 01.37 reported a study in which 22 patients 
with six or more recurrences of herpes labialis a year 
received either 400 mg aciclovir or placebo twice daily for 
4 months. There was a 53% decrease in the number of 
outbreaks for those on aciclovir, from 1.80 episodes every 
4 months with placebo to 0.85 episodes every 4 months 
with aciclovir (P=0.009). Outbreaks of herpes labialis have 
also been prevented by valaciclovir 500 mg once daily.27 
In a double-blind trial of suppressive oral valaciclovir, 
40 patients received either valaciclovir 500 mg once daily or 
placebo for 4 months; valaciclovir significantly prolonged 
the time to first recurrence compared with placebo (mean, 
16.7 weeks versus 10.6 weeks, respectively; P=0.005). There 
were also trends in favour of valaciclovir in the number of 
individuals experiencing a recurrence (35% versus 70%; 
P=0.056) and the number of recurrences per individual per 
month (0.08 versus 0.17; P=0.066). 
Conclusions 
In the past 30 years, many significant advances have been 
made in our understanding of the pathogenesis of herpes 
labialis and in our ability to manage this infection 
episodically and prophylactically with antiviral 
chemotherapy. The predominant cause of herpes labialis 
is HSV-l. HSV-2 may also infect the oral cavity, but viral 
latency and/or reactivation appear to occur much less 
readily in the trigeminal ganglion than the sacral sensory 
ganglia for this virus type. A recurrence of herpes labialis 
develops and matures very rapidly, reaching maximum 
severity within 8-16 hours of onset, leaving only a small 
window of opportunity to intervene with chemotherapy. 9 
The efficacy of nucleoside antiviral agents is lower in 
herpes labialis than in herpes genitalis, regardless of 
whether it is administered episodically or 
prophylactically. Higher doses of nucleoside antiviral 
agents may be required to achieve a comparable effect, 
such as in our recent trial of high-dose valaciclovir.27 In 
contrast, a dose-ranging study of famciclovir in recurrent 
herpes genitalis found that doses above 125 mg twice 
daily had no additional benefit. 38 In both diseases, there 
is growing evidence that only short treatment courses are 
necessary for the episodic treatment of recurrences. 27,39,40 
More media, industry and public health attention has 
been directed towards herpes genitalis than labialis. This 
is probably due to the psychological trauma of genital 
herpes, the greater efficacy of antiviral agents, the voice 
of advocacy groups, and the existence of public health 
sexually transmitted diseases programmes. Based on the 
number of persons with the illness and the severity of the 
potential complications, however, research in orofacial 
Table 5: Randomized, double-blind, placebo-controlled studies evaluating peroral antiviral prophylaxis of 
recurrent herpes labialis 
Study Study design 
Spruance et al., Parallel-group 
198835 short-term prophylaxis 
during ski vacations 
Rooney et al., Long-term crOSSOVer 
199337 study 
Raborn et al., Parallel-group 
199834 short-term prophylaxis 
during ski vacations 
Baker et a1., Long-term 
200045 parallel-group study 
NS, not significant 
Treatment arms 
Acic!ovir 400 mg 
or placebo twice daily 
for 7 days 
Acic!ovir 400 mg 
or placebo twice dai Iy 
for 4 months 
Aciclovir 800 mg 
or placebo twice daily 
for 3-7 days 
Valaciclovir 500 mg 
or placebo once daily 







Reduction in the 
frequency of recurrences 
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herpes infection should be given equal consideration. 
Important areas for future research should include 
optimization of antiviral prophylaxis and development of 
a suitable vaccine. 
